{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:20Z","timestamp":1792011260343,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.urolonc.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T11:36:31Z","timestamp":1552563391000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Androgen deprivation therapy and cardiovascular disease"],"prefix":"10.1016","volume":"38","author":[{"given":"Chiara","family":"Melloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2019.02.010_bib0002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/jnci\/djs299","article-title":"Temporal trends in cause of death among Swedish and US men with prostate cancer","volume":"104","author":"Epstein","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0003","doi-asserted-by":"crossref","first-page":"a2467","DOI":"10.1136\/bmj.a2467","article-title":"Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study","volume":"337","author":"Driver","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0004","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0005","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0007","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0009","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0011","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","article-title":"Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0012","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(01)67239-2","article-title":"Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia","volume":"154","author":"Eri","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0013","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix","volume":"186","author":"Smith","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0014","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0016","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0017","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0018","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D'Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0019","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0021","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0022","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0023","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0024","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2019.02.010_bib0026","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/bju.12732","article-title":"The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study","volume":"114","author":"Gandaglia","year":"2014","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919300651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919300651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:16:52Z","timestamp":1761041812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919300651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1078143919300651"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.02.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen deprivation therapy and cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}